Brizoton (Brinzolamide, Timolol) eye drops 5ml Бризотон

Brizoton Indications

 Decreased intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension in whom monotherapy did not result in a sufficient reduction in intraocular pressure.

Contradictions

 · Hypersensitivity to the active substances or to any of the excipients.

· Hypersensitivity to other β-blockers.

· Hypersensitivity to sulfonamides (see section "Special warnings and precautions for use").

· Conditions that are accompanied by airway hyperreactivity, including a history of bronchial asthma or bronchial asthma, severe chronic obstructive pulmonary disease.

· Sinus bradycardia, sinus node weakness syndrome, sinoauricular block, second or third degree atrioventricular block, not controlled by a pacemaker. Severe heart failure, cardiogenic shock.

· Severe allergic rhinitis.

· Hyperchloraemic acidosis (see section "Method and Dosage").

· Severe renal failure.

Dosage & Administration

The dose is 1 drop of Brizoton® eye drops in the conjunctival sac of the affected eye (s) 2 times a day.

Systemic absorption is reduced if pressed in the area of ​​the nasolacrimal opening or close the eyelids. This reduces systemic side effects and increases local activity (see section "Special warnings and precautions for use").

If a dose is missed, treatment should be continued with the next dose according to the dosing schedule. The dose should not exceed 1 drop in the affected eye (s) 2 times a day.

If another ophthalmic antiglaucoma agent is replaced with Brizoton® eye drops, the other product should be discontinued by starting Brizoton® eye drops the next day.